RU2640180C2 - Способ адъювантного лечения рака - Google Patents

Способ адъювантного лечения рака Download PDF

Info

Publication number
RU2640180C2
RU2640180C2 RU2015105821A RU2015105821A RU2640180C2 RU 2640180 C2 RU2640180 C2 RU 2640180C2 RU 2015105821 A RU2015105821 A RU 2015105821A RU 2015105821 A RU2015105821 A RU 2015105821A RU 2640180 C2 RU2640180 C2 RU 2640180C2
Authority
RU
Russia
Prior art keywords
melanoma
dabrafenib
trametinib
amount
treatment
Prior art date
Application number
RU2015105821A
Other languages
English (en)
Russian (ru)
Other versions
RU2015105821A (ru
Inventor
Сильви Лакерр
Питер Ф. Лебовиц
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2640180(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2015105821A publication Critical patent/RU2015105821A/ru
Application granted granted Critical
Publication of RU2640180C2 publication Critical patent/RU2640180C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2015105821A 2012-09-04 2013-08-30 Способ адъювантного лечения рака RU2640180C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261696375P 2012-09-04 2012-09-04
US61/696,375 2012-09-04
PCT/US2013/057432 WO2014039375A1 (en) 2012-09-04 2013-08-30 Method of adjuvant cancer treatment

Publications (2)

Publication Number Publication Date
RU2015105821A RU2015105821A (ru) 2016-10-20
RU2640180C2 true RU2640180C2 (ru) 2017-12-26

Family

ID=50237545

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015105821A RU2640180C2 (ru) 2012-09-04 2013-08-30 Способ адъювантного лечения рака

Country Status (20)

Country Link
US (7) US20150216868A1 (enExample)
EP (2) EP2892535B1 (enExample)
JP (3) JP2015527374A (enExample)
KR (1) KR102134585B1 (enExample)
CN (2) CN104582706A (enExample)
AU (2) AU2013313050A1 (enExample)
BR (1) BR112015004578A2 (enExample)
CA (1) CA2882437C (enExample)
CY (1) CY1124812T1 (enExample)
DK (1) DK2892535T3 (enExample)
ES (1) ES2900825T3 (enExample)
HR (1) HRP20211817T1 (enExample)
HU (1) HUE056646T2 (enExample)
IN (1) IN2015KN00449A (enExample)
LT (1) LT2892535T (enExample)
PL (1) PL2892535T3 (enExample)
PT (1) PT2892535T (enExample)
RU (1) RU2640180C2 (enExample)
SI (1) SI2892535T1 (enExample)
WO (1) WO2014039375A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104582706A (zh) 2012-09-04 2015-04-29 葛兰素史克有限责任公司 辅助癌症治疗的方法
CN111534580B (zh) 2013-12-28 2024-06-04 夸登特健康公司 用于检测遗传变异的方法和系统
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018203219A1 (en) * 2017-05-02 2018-11-08 Novartis Ag Combination therapy
US11890286B2 (en) * 2018-04-17 2024-02-06 The University Of Chicago Methods and compositions for treating cancer
CN109106893B (zh) * 2018-11-12 2021-04-20 上海市中西医结合医院 一种调节肠道屏障功能的中药复方制剂及其制备方法
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
CN114981298B (zh) * 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2452482C2 (ru) * 2005-02-18 2012-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Комбинация и способы введения терапевтических средств и комбинированной терапии
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883289B1 (ko) * 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
HUE060206T2 (hu) * 2009-10-16 2023-02-28 Novartis Ag MEK gátlót és B-Raf gátlót tartalmazó kombináció
CN104582706A (zh) 2012-09-04 2015-04-29 葛兰素史克有限责任公司 辅助癌症治疗的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2452482C2 (ru) * 2005-02-18 2012-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Комбинация и способы введения терапевтических средств и комбинированной терапии
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BATCHELOR J.S. MEK and BRAF Therapy Combo Promising for Advanced Melanoma//2011 ASCO Annual Meeting, онлайн, найдено в Интернет на (http://www.onclive.com/conference-coverage/asco-2011/mek-and-braf-therapy-combo-promising-for-advanced-melanoma), 13.06.2017. *
МИХНИН А.Е. и др. Злокачественная меланома кожи: поиски стандартов лечения//Практическая онкология, 2001. - N 4(8), с. 69-72. *

Also Published As

Publication number Publication date
PL2892535T3 (pl) 2022-01-31
JP2015527374A (ja) 2015-09-17
CA2882437A1 (en) 2014-03-13
US20180338979A1 (en) 2018-11-29
JP6684941B2 (ja) 2020-04-22
IN2015KN00449A (enExample) 2015-07-17
CA2882437C (en) 2021-03-02
US20200054641A1 (en) 2020-02-20
EP2892535A1 (en) 2015-07-15
PT2892535T (pt) 2021-12-15
JP6511117B2 (ja) 2019-05-15
US20170202842A1 (en) 2017-07-20
JP2019142899A (ja) 2019-08-29
ES2900825T3 (es) 2022-03-18
AU2016244279B2 (en) 2018-01-04
HK1206642A1 (en) 2016-01-15
LT2892535T (lt) 2021-12-10
RU2015105821A (ru) 2016-10-20
BR112015004578A2 (pt) 2017-07-04
US20210060021A1 (en) 2021-03-04
CY1124812T1 (el) 2022-11-25
US20260207608A1 (en) 2026-07-23
EP2892535B1 (en) 2021-09-22
WO2014039375A1 (en) 2014-03-13
HRP20211817T1 (hr) 2022-03-04
US20150216868A1 (en) 2015-08-06
EP2892535A4 (en) 2016-04-13
AU2013313050A1 (en) 2015-03-26
DK2892535T3 (da) 2022-01-03
HUE056646T2 (hu) 2022-02-28
KR20150047619A (ko) 2015-05-04
KR102134585B1 (ko) 2020-07-17
SI2892535T1 (sl) 2022-01-31
CN107308164A (zh) 2017-11-03
CN104582706A (zh) 2015-04-29
JP2018058859A (ja) 2018-04-12
US20230330091A1 (en) 2023-10-19
AU2016244279A1 (en) 2016-11-03
EP3981408A1 (en) 2022-04-13
US10869869B2 (en) 2020-12-22

Similar Documents

Publication Publication Date Title
US10869869B2 (en) Method of adjuvant cancer treatment
EP3021848B1 (en) Treatment for melanoma
TWI714816B (zh) 用於治療腺樣囊性癌之新穎苯磺醯胺衍生物的醫藥組成物
WO2015179075A1 (en) Treatment for melanoma
CN113613656A (zh) 用图卡替尼治疗乳腺癌的方法
JP2020519576A (ja) 肝細胞癌の治療
HK40070843A (en) Dabrafenib and trametinib in a method of adjuvant cancer treatment
KR20180129795A (ko) 렌바티닙 및 에베롤리무스를 사용한 신세포 암종의 치료
HK1206642B (en) Method of adjuvant cancer treatment
RU2728932C2 (ru) Терапевтическое средство для лечения рака желчевыводящих путей
TW202532086A (zh) 治療對卡介苗療法無反應之高風險非肌肉侵襲性膀胱癌之方法
HK40111558A (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
WO2026021478A1 (zh) Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法
WO2023041978A1 (es) COMPOSICIONES SINÉRGICAS DE COMPUESTOS CONTRA EL COMPLEJO HETERODIMÉRICO K-RAS4B/PDE6δ PARA EL TRATAMIENTO DE CÁNCER DE PÁNCREAS
US9872882B2 (en) Aurantiamide dipeptide derivatives for treatment or prevention of angiogenesis-related diseases
WO2026021460A1 (zh) 治疗前列腺癌的方法
HK40009453A (en) Pharmaceutical composition of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma
WO2025245463A9 (en) Combination therapies